250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 250,204 shares of the biotechnology company's stock, valued at approximately $3,806,000. Point72 Asset Management L.P. owned about 0.55% of Capricor Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Main Street Financial Solutions LLC increased its stake in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock valued at $131,000 after acquiring an additional 7,500 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Capricor Therapeutics during the third quarter worth $133,000. Bank of New York Mellon Corp grew its stake in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after buying an additional 9,040 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Capricor Therapeutics during the third quarter worth $161,000. Finally, Oppenheimer & Co. Inc. grew its stake in shares of Capricor Therapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company's stock worth $1,040,000 after buying an additional 13,762 shares during the last quarter. 21.68% of the stock is owned by institutional investors.

Insider Activity at Capricor Therapeutics

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the company's stock in a transaction dated Friday, September 20th. The shares were purchased at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the acquisition, the insider now owns 7,090,351 shares of the company's stock, valued at approximately $38,004,281.36. This trade represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on CAPR. Oppenheimer reissued an "outperform" rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, September 25th. Cantor Fitzgerald boosted their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a research note on Thursday, November 14th. Piper Sandler began coverage on shares of Capricor Therapeutics in a research note on Monday, October 21st. They issued an "overweight" rating and a $35.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Price Performance

CAPR stock traded up $0.35 during midday trading on Monday, hitting $15.21. The stock had a trading volume of 854,108 shares, compared to its average volume of 1,185,684. Capricor Therapeutics Inc has a 1-year low of $3.24 and a 1-year high of $23.40. The business has a fifty day moving average price of $18.69 and a two-hundred day moving average price of $9.78.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.